retatrutide safety retatrutide clinical trial Availability & Timeline retatrutide safety trial results Retatrutide

Eli Lilly's retatrutide (LY3437943) was in Phase 3 trials as of 2025, with at least one stage expected to conclude in May 2026 [6]

Your Klinic provider will guide you on proper injection techniques and site rotation for optimal results

As with all medications, retatrutide has some adverse effects

Manufacturers like Eli Lilly and Novo Nordisk plan to manufacture and distribute GLP-1 drugs in the future

Subcutaneous injection technique is consistent across GLP-1 class drugs, making this 464,000-view walkthrough directly applicable to retatrutide pen and vial administration

By understanding these connections and taking proactive steps to support hydration and electrolyte balance, you can harness the benefits of these diabetes and weight loss medications while maintaining the gut health thats so essential to your overall well-being